Spike Protein News and Research

RSS

Immunity to SARS-CoV-2 could last longer than originally believed

One year after infection by SARS-CoV-2, most people maintain anti-Spike antibodies regardless of the severity of their symptoms, according to a study with healthcare workers co-led by the Barcelona Institute for Global Health (ISGlobal), the Catalan Health Institute (ICS) and the Jordi Gol Institute (IDIAP JG), with the collaboration of the Daniel Bravo Andreu Private Foundation.

2 Jul 2021

Engineered T cells prevent translational shutdown in SARS-CoV-2 infected cells

In a paper recently uploaded to the preprint server bioRxiv* by Schamel et al. (June 25th, 2021) engineered T cells against SARS-CoV-2 are tested against a range of cells in vitro, finding that the treatment could be used to restore cellular immune function and suppress SARS-CoV-2.

1 Jul 2021

Mutations in the spike proteins of SARS-CoV-2 select for amino acid changes, increasing protein stability

A team of researchers recently demonstrated that mutations in the S protein of SARS-CoV-2 select for amino acid changes that result in a more stable protein than would otherwise be expected.

1 Jul 2021

Cryo-EM structure of neutralizing antibody 5-7 in complex with SARS CoV-2 spike

Researchers from the US recently reported the 3.7 Å resolution cryo-EM structure of an NTD-directed neutralizing antibody 5-7 that forms a complex with SARS-CoV-2 spike protein. They also presented the neutralization data against VOC and studied the recognized epitope.

1 Jul 2021

Grapevine leaf extract inhibits SARS-CoV-2 and HSV-1 replication in the lab

Researchers in Italy have shown that leaf extract from the common grapevine – Vitis vinifera – exhibits significant antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

1 Jul 2021

Study highlights the importance of T cell cross reactivity in stopping severe COVID-19 infections

Researchers at La Jolla Institute for Immunology have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.

1 Jul 2021

Study explores lectins from plants, fungi, algae and cyanobacteria as pan-coronavirus inhibitors

In a recently published article scientists have provided a detailed description of the utility of mannose-specific lectins in preventing coronavirus infections. They have specifically explained how mannose-specific lectins derived from plants, algae, fungi, and bacteria selectively bind N-glycans present on the surface of viral spike protein and how such interactions can be medically utilized to control coronavirus transmission.

1 Jul 2021

Study evaluates neutralizing antibody responses elicited by the Pfizer/BioNTech COVID-19 vaccine

A recent Diagnostics study discusses the specific antibody response that occurred in individuals after they had received the SARS-CoV-2 vaccine.

1 Jul 2021

Could peridomestic mammals act as zoonotic reservoirs for SARS-CoV-2?

In new research from researchers in the USA and Australia peridomestic mammals, which live in and around human habitations, have been investigated to ascertain how SARS-CoV-2 can affect species external to, but in close proximity to, the human population.

1 Jul 2021

Researchers identify proteins that contribute to the pathogenicity of COVID-19 virus

Researchers at Texas Biomedical Research Institute (Texas Biomed) have narrowed down the proteins enabling SARS-CoV-2 to cause disease.

1 Jul 2021

New study maps evolutionary history and interrelationships of protein domains

Proteins have been quietly taking over our lives since the COVID-19 pandemic began. We've been living at the whim of the virus's so-called "spike" protein, which has mutated dozens of times to create increasingly deadly variants. But the truth is, we have always been ruled by proteins. At the cellular level, they're responsible for pretty much everything.

1 Jul 2021

COVID mRNA vaccines induce antibodies against three SARS-CoV-2 variants

Researchers at the Institute of Biomedicine, the University of Turku in Finland showed that the blood of BNT162b2-vaccinated health care workers effectively neutralized the SARS-CoV-2 variant with the D614G substitution and the B.1.1.7 variant (Alpha variant) after the second dose.

1 Jul 2021

Ion channel conserved in coronaviruses a potential new drug target for COVID therapeutics

To this end, a recent study published in Nature Structural & Molecular Biology discusses the structures of the SARS-CoV-2 ORF3a using cryo-electron microscopy (cryo-EM).

30 Jun 2021

Study highlights changes within SARS-CoV-2 variants that could be exploited to design effective inhibitors

A computational study that analyzes and explores the time-based structures of the SARS-CoV-2 variants with specific spike (S) protein mutations is discussed here.

30 Jun 2021

First demonstration of COVID-19-like response by an essential virus encoded protein by SARS-CoV-2 in vivo

Researchers from collaborating universities in Virginia have recently utilized transgenic mice to explore the effects of SARS-CoV-2 on associated lung injury.

30 Jun 2021

Alpha variant mutations help SARS-CoV-2 overcome evolutionary weaknesses

The study, published in the journal Cell Reports, showed that the mutations in the virus, particularly the deletion of two amino acids H69/V70 seen in the Alpha variant (B.1.1.7), enables the virus to overcome weaknesses as it evolves.

30 Jun 2021

Antibody development against SARS-CoV-2 following Moderna vaccine

In a paper recently uploaded to the preprint server medRxiv* by Belda et al. (June 27th, 2021) two seroconversion panels containing the sera of individuals that received the Moderna (mRNA-1273) vaccine are compared, and the impact on neutralizing IgG antibody titers in these individuals is analyzed.

30 Jun 2021

Study provides important insights into early stages of SARS-CoV-2 infection

Researchers in the UK have provided important new insights into the early stages of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

30 Jun 2021

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

A team of US-based scientists recently developed a novel vaccine candidate against SARS-CoV-2, the causative pathogen of COVID-19. The vaccine is composed of extracellular vesicles of Salmonella typhimurium incorporated with the spike receptor-binding domain (RBD) of SARS-CoV-2. Upon intranasal administration in hamsters, the vaccine induces strong blood antibody titers and protects against severe COVID-19.

30 Jun 2021

Alpha (B.1.1.7) SARS-CoV-2 variant associated with more severe disease in hospitalized women

Researchers in the UK have conducted a study showing that infection with the B.1.1.7 (Alpha) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be associated with an increased risk of death or intensive care unit (ITU) admission among women, compared with non-B.1.1.7 infection.

29 Jun 2021

Spike Protein News and Research

Immunity to SARS-CoV-2 could last longer than originally believed

Engineered T cells prevent translational shutdown in SARS-CoV-2 infected cells

Mutations in the spike proteins of SARS-CoV-2 select for amino acid changes, increasing protein stability

Cryo-EM structure of neutralizing antibody 5-7 in complex with SARS CoV-2 spike

Grapevine leaf extract inhibits SARS-CoV-2 and HSV-1 replication in the lab

Study highlights the importance of T cell cross reactivity in stopping severe COVID-19 infections

Study explores lectins from plants, fungi, algae and cyanobacteria as pan-coronavirus inhibitors

Study evaluates neutralizing antibody responses elicited by the Pfizer/BioNTech COVID-19 vaccine

Could peridomestic mammals act as zoonotic reservoirs for SARS-CoV-2?

Researchers identify proteins that contribute to the pathogenicity of COVID-19 virus

New study maps evolutionary history and interrelationships of protein domains

COVID mRNA vaccines induce antibodies against three SARS-CoV-2 variants

Ion channel conserved in coronaviruses a potential new drug target for COVID therapeutics

Study highlights changes within SARS-CoV-2 variants that could be exploited to design effective inhibitors

First demonstration of COVID-19-like response by an essential virus encoded protein by SARS-CoV-2 in vivo

Alpha variant mutations help SARS-CoV-2 overcome evolutionary weaknesses

Antibody development against SARS-CoV-2 following Moderna vaccine

Study provides important insights into early stages of SARS-CoV-2 infection

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

Alpha (B.1.1.7) SARS-CoV-2 variant associated with more severe disease in hospitalized women

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News